For patients hospitalized with COVID-19, tocilizumab plus standard care has been shown to cut the risk for death, shorten hospitalization time, and reduce the need for mechanical ventilation.
Source: https://www.medscape.com/viewarticle/953748?src=mbl_msp_android&ref=share